There are 29,003 new cases of coronavirus in Italy in the last 24 hours
.
The new bulletin of the Ministry of Health reports it.
The deaths are 822. The total cases of covid exceed one and a half million, reaching 1,509,875.
Intensive care has
dropped for the first time since the start of the second wave.
From the 3,848 patients of yesterday to the 3,846 of today, with a decrease of two units.
For the third consecutive day, the number of hospitalized patients in the medical area is also confirmed, going from 34,313 yesterday to 34,038 today, with a drop of 275. The discharged or healed today are 661,180, 24,031 more than yesterday.
To date, in Italy, the currently positive are 795,961.
"
To beat the virus, a vaccine will be needed, that will be the definitive moment
for this sad page to be turned to some extent and can constitute a sad and dramatic component of our past".
The commissioner for the coronavirus emergency, Domenico Arcuri, said this during a press conference.
THE PRESS CONFERENCE OF COMMISSIONER ARCURI
"
The Immuni app
- said Arcuri in another passage -
has increased the number of downloads to over 10 million
. It has not yet produced the results, in terms of discovery of the infected, that could be expected".
"I think the app is a very important tool. But for it to be effective you need a relationship of mutual collaboration between the app and the downloader - he continued -. The message we conveyed was not powerful enough for this to happen. . I'm not sure that downloads correspond to an equal number of the correct functioning of the app ".
Meanwhile, the anti Covid vaccine candidate developed by the University of Oxford, in collaboration among others with the Irbm of Pomezia, requires "additional" studies.
Pascal Soriot, number one of the pharmaceutical company AstraZeneca, partner of the project, admitted this today, in an interview with Bloomberg, a few days after the publication of the first results on the experiment that indicated an efficacy of the prototype between 62 and 90% depending on the types of dosage (about 70% average).
Those results had subsequently been the subject of requests for clarification and doubts on some data in the international scientific community.
"The news that the Covid vaccine candidate developed by the University of Oxford needs further studies
on the one hand, because the time of delivery is moving away, on the other it reassures us because it guarantees us
".
This was stated by Stefano Vella, infectious disease specialist, professor of global health at the Catholic University of Rome and former president of Aifa.
"I hypothesize that the studies to be done - he added - may concern the doses: it is a question of understanding why a vaccination with half the dose first (prime dose) and then the booster with a full dose works better than otherwise. So the study should be of biological type, ie on the response of the immune system, and not a return to the clinical trial "
